- Home
- BKYI vs TOVX Comparison
BKYI vs TOVX Comparison
Compare BKYI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | TOVX |
|---|---|---|
| Founded | 1993 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.3M |
| IPO Year | 1997 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BKYI | TOVX |
|---|---|---|
| Price | $0.74 | $0.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.1M | 2.7M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,316,050.00 | N/A |
| Revenue This Year | $7.45 | N/A |
| Revenue Next Year | $23.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.62 | $0.20 |
| 52 Week High | $3.68 | $2.08 |
Technical Indicators
Market Signals| Indicator | BKYI | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 46.09 |
| Support Level | $0.68 | $0.20 |
| Resistance Level | $1.07 | $0.27 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.22 | 59.30 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.